Tadevosyan Artavazd, Maclaughlin Eric J, Karamyan Vardan T
Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada;
Patient Relat Outcome Meas. 2011 Jul;2:27-39. doi: 10.2147/PROM.S8384. Epub 2011 Jan 25.
Hypertension in the elderly is one of the main risk factors of cardiovascular and cerebrovascular diseases. Knowledge regarding the mechanisms of hypertension and specific considerations in managing hypertensive elderly through pharmacological intervention(s) is fundamental to improving clinical outcomes. Recent clinical studies in the elderly have provided evidence that angiotensin II type 1 (AT(1)) receptor antagonists can improve clinical outcomes to a similar or, in certain populations, an even greater extent than other classical arterial blood pressure-lowering agents. This newer class of antihypertensive agents presents several benefits, including potential for improved adherence, excellent tolerability profile with minimal first-dose hypotension, and a low incidence of adverse effects. Thus, AT(1) receptor antagonists represent an appropriate option for many elderly patients with hypertension, type 2 diabetes, heart failure, and/or left ventricular dysfunction.
老年人高血压是心脑血管疾病的主要危险因素之一。了解高血压的发病机制以及通过药物干预治疗老年高血压患者的特殊注意事项对于改善临床结局至关重要。近期针对老年人的临床研究表明,血管紧张素II 1型(AT(1))受体拮抗剂在改善临床结局方面,与其他传统的动脉降压药物效果相当,在某些人群中甚至更优。这类新型抗高血压药物具有多种益处,包括可能提高依从性、耐受性良好,首剂低血压发生率极低,不良反应发生率也较低。因此,AT(1)受体拮抗剂是许多患有高血压、2型糖尿病、心力衰竭和/或左心室功能障碍的老年患者的合适选择。